Genelux Corporation (NASDAQ: GNLX) is a Healthcare company (Biotechnology) with a market capitalization of $90M. The Maz Rating grades it against the other companies in its sector.
Genelux Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.00, Genelux Corporation trades at 11141.7x sales and 9.7x book value. Over the last twelve months it generated about $8122 of revenue and a net loss of $42M. It runs a gross margin of -2975.0%, an operating margin of -472737.5% and a net margin of -451600.0%. It shows return on equity of -241.8%, return on invested capital of -328.2% and a free cash flow yield of -33.1%. On the balance sheet: a debt-to-equity ratio of 0.26 and a current ratio of 1.16. Over the past 52 weeks the share price ranged from $1.77 to $5.89, with a beta of 0.58.
Genelux Corporation does not currently pay a dividend.
3 Wall Street analyst ratings cover the stock: 2 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Genelux Corporation (GNLX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.29% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.76% / 30% · Interest income / Revenue 11200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.29% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 9.76% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 11200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.29% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 9.76% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.78% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 71.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 1.51% / 33.33% · (Cash+ST Inv) / Total Assets 50.7% / 33.33% · (Cash+Recv) / Total Assets 50.7% / 33.33% · Interest income / Revenue 11200000.0% / 5% | Fail |
No. As of September 2026, Genelux Corporation (GNLX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Genelux Corporation is over the AAOIFI limit on Interest income / Revenue.
About 11200000.0% of each dividend: Genelux Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.